Ozanimod hydrochloride

• CAT Number: I034107
• CAS Number: 1618636-37-5
• Molecular Formula: C23H25ClN4O3
• Molecular Weight: 440.928
• Purity: 98%
• Synonyms: Ozanimod hydrochloride; Ozanimod HCl
• Target: LPL Receptor
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: (S)-5-(3-(1-((2-hydroxyethyl)amino)-2,3-dihydro-1H-inden-4-yl)-1,2,4-oxadiazol-5-yl)-2-isopropoxybenzonitrile hydrochloride
• InChI: InChI=1S/C23H24N4O3.ClH/c1-14(2)29-21-9-6-15(12-16(21)13-24)23-26-22(27-30-23)19-5-3-4-18-17(19)7-8-20(18)25-10-11-28;/h3-6,9,12,14,20,25,28H,7-8,10-11H2,1-2H3;1H/t20-;/m0./s1
• InChIKey: HAOOCAKHSFYDBU-BDQAORGHSA-N
• SMILES: N#CC1=CC(C2=NC(C3=CC=CC4=C3CC[C@@H]4NCCO)=NO2)=CC=C1OC(C)C.[H]Cl

Ozanimod hydrochloride is a novel dual selective S1PR1 and S1PR5 modulator.

Reference

1: Harris S, Tran JQ, Southworth H, Spencer CM, Cree BAC, Zamvil SS. Effect of the sphingosine-1-phosphate receptor modulator ozanimod on leukocyte subtypes in relapsing MS. Neurol Neuroimmunol Neuroinflamm. 2020 Jul 31;7(5):e839. doi: 10.1212/NXI.0000000000000839. PMID: 32737072; PMCID: PMC7413711.
2: Karuppuchamy T, Tyler CJ, Lundborg LR, Pérez-Jeldres T, Kimball AK, Clambey ET, Jedlicka P, Rivera-Nieves J. Sphingosine-1-Phosphate Lyase Inhibition Alters the S1P Gradient and Ameliorates Crohn’s-Like Ileitis by Suppressing Thymocyte Maturation. Inflamm Bowel Dis. 2020 Jan 6;26(2):216-228. doi: 10.1093/ibd/izz174. PMID: 31807751; PMCID: PMC6943703.
3: Panés J, Salas A. Past, Present and Future of Therapeutic Interventions Targeting Leukocyte Trafficking in Inflammatory Bowel Disease. J Crohns Colitis. 2018 Aug 22;12(suppl_2):S633-S640. doi: 10.1093/ecco-jcc/jjy011. PMID: 30137311.
4: Cohen JA, Comi G, Arnold DL, Bar-Or A, Selmaj KW, Steinman L, Havrdová EK, Cree BA, Montalbán X, Hartung HP, Huang V, Frohna P, Skolnick BE, Kappos L; RADIANCE Trial Investigators. Efficacy and safety of ozanimod in multiple sclerosis: Dose-blinded extension of a randomized phase II study. Mult Scler. 2019 Aug;25(9):1255-1262. doi: 10.1177/1352458518789884. Epub 2018 Jul 25. PMID: 30043658; PMCID: PMC6681431.
5: Buc M. New biological agents in the treatment of multiple sclerosis. Bratisl Lek Listy. 2018;119(4):191-197. doi: 10.4149/BLL_2018_035. PMID: 29663814.
6: Faissner S, Gold R. Oral Therapies for Multiple Sclerosis. Cold Spring Harb Perspect Med. 2019 Jan 2;9(1):a032011. doi: 10.1101/cshperspect.a032011. PMID: 29500302; PMCID: PMC6314072.
7: Tran JQ, Hartung JP, Tompkins CA, Frohna PA. Effects of High- and Low-Fat Meals on the Pharmacokinetics of Ozanimod, a Novel Sphingosine-1-Phosphate Receptor Modulator. Clin Pharmacol Drug Dev. 2018 Aug;7(6):634-640. doi: 10.1002/cpdd.409. Epub 2017 Nov 10. PMID: 29125718; PMCID: PMC6099448.
8: Danese S, Furfaro F, Vetrano S. Targeting S1P in Inflammatory Bowel Disease: New Avenues for Modulating Intestinal Leukocyte Migration. J Crohns Colitis. 2018 Aug 22;12(suppl_2):S678-S686. doi: 10.1093/ecco-jcc/jjx107. PMID: 28961752.
9: Chaudhry BZ, Cohen JA, Conway DS. Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple Sclerosis. Neurotherapeutics. 2017 Oct;14(4):859-873. doi: 10.1007/s13311-017-0565-4. PMID: 28812220; PMCID: PMC5722770.
10: Karuppuchamy T, Behrens EH, González-Cabrera P, Sarkisyan G, Gima L, Boyer JD, Bamias G, Jedlicka P, Veny M, Clark D, Peach R, Scott F, Rosen H, Rivera- Nieves J. Sphingosine-1-phosphate receptor-1 (S1P1) is expressed by lymphocytes, dendritic cells, and endothelium and modulated during inflammatory bowel disease. Mucosal Immunol. 2017 Jan;10(1):162-171. doi: 10.1038/mi.2016.35. Epub 2016 Apr 6. PMID: 27049060; PMCID: PMC5053832.